Treatment landscape of triple-negative breast cancer — expanded options, evolving needs

Giampaolo Bianchini; Carmine De Angelis; Luca Licata; Luca Gianni

doi:10.1038/s41571-021-00565-2

Keywords

Triple-negative breast cancerMedicineBreast cancerTumor microenvironmentCancerDiseaseDrug developmentBioinformaticsOncologyCancer researchInternal medicineDrugPharmacologyBiology

Affiliated Institutions

Related Publications

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Andreas D. Hartkopf , Florin‐Andrei Taran , Markus Wallwiener +4 more

Immune checkpoint inhibition represents a major recent breakthrough in the treatment of malignant diseases including breast cancer. Blocking the programmed death receptor-1 (PD-...

2016 Breast Care 30893 citations

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

Rita Nanda , Laura Q.M. Chow , Elizabeth Claire Dees +9 more

Purpose Immune checkpoint inhibition has been demonstrated to be an effective anticancer strategy. Several lines of evidence support the study of immunotherapy in triple-negativ...

2016 Journal of Clinical Oncology 1427 citations

Pembrolizumab for Early Triple-Negative Breast Cancer

Peter Schmid , Javier Cortés , Lajos Pusztai +18 more

Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plu...

2020 New England Journal of Medicine 2718 citations

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés , David W. Cescon , Hope S. Rugo +97 more

Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative breast cancer. We aimed to examine whether the add...

2020 The Lancet 1658 citations

The future of immune checkpoint therapy

Padmanee Sharma , James P. Allison

Immune checkpoint therapy, which targets regulatory pathways in T cells to enhance antitumor immune responses, has led to important clinical advances and provided a new weapon a...

2015 Science 4591 citations

Publication Info

Year: 2021
Type: review
Volume: 19
Issue: 2
Pages: 91-113
Citations: 1152
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Treatment landscape of triple-negative breast cancer — expanded options, evolving needs

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1152

OpenAlex

Cite This

APA Style

                            
                                
                                    Giampaolo Bianchini, 
                                
                                    Carmine De Angelis, 
                                
                                    Luca Licata
                                
                                et al.
                            
                            (2021). 
                            Treatment landscape of triple-negative breast cancer — expanded options, evolving needs. 
                            Nature Reviews Clinical Oncology
                            , 19
                            (2)
                            , 91-113.
                            https://doi.org/10.1038/s41571-021-00565-2
                        

Identifiers

DOI: 10.1038/s41571-021-00565-2